Dyne Therapeutics
76 hedge funds and large institutions have $754M invested in Dyne Therapeutics in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 14 reducing their positions, and 14 closing their positions.
107% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 14
41% more capital invested
Capital invested by funds: $533M → $754M (+$220M)
3.21% more ownership
Funds ownership: 66.73% → 69.94% (+3.2%)
1% more funds holding
Funds holding: 75 → 76 (+1)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.7M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.41M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$6.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$21.6M |
| 2 |
CC
Casdin Capital
New York
|
-$9.47M |
| 3 |
Janus Henderson Group
London,
|
-$5.58M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.37M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.28M |
DYN Hedge Fund Activity: Q2 2021 in Review
76 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q2 2021, worth a combined $754M — up 41% from $533M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new DYN positions and 14 closed out — a net gain of 1 holder — while 29 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $13.7M. The largest seller was Logos Global Management, cutting an estimated $21.6M.
- 76 institutional investors held Dyne Therapeutics (DYN) as of Q2 2021, up from 75 in Q1 2021.
- Funds reported $754M of Dyne Therapeutics stock for Q2 2021, up 41% quarter-over-quarter.
- 15 funds opened new Dyne Therapeutics positions in Q2 2021 and 14 closed out, a net change of +1 holder.
- The largest Dyne Therapeutics buyer in Q2 2021 was BlackRock, an estimated $13.7M added.
- The largest Dyne Therapeutics seller in Q2 2021 was Logos Global Management, an estimated $21.6M sold.
Based on aggregated 13F filings for Q2 2021.